Therapy News and Research

RSS

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Added benefit of dabrafenib not proven

Dabrafenib has been approved in Germany since August 2013 for the treatment of advanced melanoma. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the appropriate comparator therapy.

7 Jan 2014

Landes Bioscience releases special issue on sepsis

A special issue on sepsis has been released by the publisher Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Virulence have been authored by world-class investigators and provide new insights into both the pathogen-related factors and the host defense mechanisms that lead to septic shock and contribute to its resolution or fatal outcome.

7 Jan 2014

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.

7 Jan 2014

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.

7 Jan 2014

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Matt G. Kushner, Ph.D., professor of Psychiatry, University of Minnesota (Minneapolis) has earned the latest Dan Anderson Research Award for his study examining the effectiveness of a hybrid cognitive behavioral therapy in the treatment of individuals with co-occurring anxiety disorders and alcohol dependence.

7 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

Health insurance is a fast changing landscape in the United States with the implementation of ObamaCare, also known as The Affordable Health Care Act. Health insurance companies are doing something called cost shifting where the cost of care gets shifted onto the patients. For people who suffer with obstructive sleep apnea, this is can be a costly shift.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

Second module of PMA application submitted to FDA for Sapheon's VenaSeal Sapheon Closure System

Sapheon Inc. announced today that it has submitted the second module of the pre-market approval application for the VenaSeal Sapheon Closure System to the U.S. Food and Drug Administration.

7 Jan 2014

New ways to treat substance abuse, neurological diseases and mental illnesses

Researchers at the University at Buffalo have found a way to change alcohol drinking behavior in rodents, using the emerging technique of optogenetics, which uses light to stimulate neurons.

7 Jan 2014

Research: Daily meditation may improve symptoms of anxiety and depression

Some 30 minutes of meditation daily may improve symptoms of anxiety and depression, a new Johns Hopkins analysis of previously published research suggests.

7 Jan 2014

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Research from the National Institute of Respiratory Diseases informs that besides smoking, there are other factors associated to the development of lung cancer such as the smoke from burning lumber and coal, as well as pollutant particles.

7 Jan 2014

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Cancer researchers at the University of Chicago and five other leading institutions will share equally in a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Ludwig Cancer Research is an international community of researchers dedicated to pursuing life-changing discoveries to alter the course of cancer.

7 Jan 2014

Autism Speaks grants $2.7M to develop potential treatments for ASD, increase access to high-quality early intervention

Autism Speaks, the world's leading autism science and advocacy organization, today announced the award of nearly $2.7 million for the funding of 13 new research projects over the next three years.

6 Jan 2014

Researchers hope to improve treatment, survival rates of ischemic heart disease

Researchers at Case Western Reserve University and University Hospitals Case Medical Center hope to improve treatment and survival rates of ischemic heart disease patients by providing doctors an unprecedented look at the stents they place in coronary arteries.

6 Jan 2014

Therapy News and Research

IQWiG study finds no added benefit of teriflunomide

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Added benefit of dabrafenib not proven

Landes Bioscience releases special issue on sepsis

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

Blueprint Medicines closes $25 million Series B financing

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

ObamaCare can be a costly shift for people suffering with obstructive sleep apnea

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Second module of PMA application submitted to FDA for Sapheon's VenaSeal Sapheon Closure System

New ways to treat substance abuse, neurological diseases and mental illnesses

Research: Daily meditation may improve symptoms of anxiety and depression

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Autism Speaks grants $2.7M to develop potential treatments for ASD, increase access to high-quality early intervention

Researchers hope to improve treatment, survival rates of ischemic heart disease

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News